Your browser doesn't support javascript.
loading
Patient perspectives following pharmacogenomics results disclosure in an integrated health system.
Lemke, Amy A; Hulick, Peter J; Wake, Dyson T; Wang, Chi; Sereika, Annette W; Yu, Kristen Dilzell; Glaser, Nicole S; Dunnenberger, Henry M.
Affiliation
  • Lemke AA; Center for Personalized Medicine, NorthShore University HealthSystem, 1001 University Place, Suite 160, Evanston, IL 60201, USA.
  • Hulick PJ; Center for Personalized Medicine, NorthShore University HealthSystem, 1001 University Place, Suite 160, Evanston, IL 60201, USA.
  • Wake DT; Center for Personalized Medicine, NorthShore University HealthSystem, 1001 University Place, Suite 160, Evanston, IL 60201, USA.
  • Wang C; Biostatistics & Research Informatics, NorthShore University HealthSystem, 1001 University Place, Suite 146, Evanston, IL 60201, USA.
  • Sereika AW; Center for Personalized Medicine, NorthShore University HealthSystem, 1001 University Place, Suite 160, Evanston, IL 60201, USA.
  • Yu KD; Center for Personalized Medicine, NorthShore University HealthSystem, 1001 University Place, Suite 160, Evanston, IL 60201, USA.
  • Glaser NS; Center for Personalized Medicine, NorthShore University HealthSystem, 1001 University Place, Suite 160, Evanston, IL 60201, USA.
  • Dunnenberger HM; Center for Personalized Medicine, NorthShore University HealthSystem, 1001 University Place, Suite 160, Evanston, IL 60201, USA.
Pharmacogenomics ; 19(4): 321-331, 2018 03.
Article in En | MEDLINE | ID: mdl-29469671
ABSTRACT

AIM:

To assess patient perceptions and utilization of pharmacogenomics (PGx) testing in an integrated community health system.

METHODS:

Fifty-seven patients completed an online survey assessing their experiences with PGx testing offered through two

methods:

a designated PGx clinic or direct access in-home testing.

RESULTS:

The majority of participants perceived PGx testing as helpful in their healthcare and reported understanding their results. Some had concerns about privacy and discrimination; most lacked familiarity with the Genetic Information Nondiscrimination Act. There were no significant differences in views between participants tested through either model.

CONCLUSION:

Participants reported value in both methods of PGx testing. Patient experiences, understanding and result utilization will play an important role in informing future development and implementation of PGx programs.
Subject(s)
Key words

Full text: 1 Database: MEDLINE Main subject: Pharmacogenetics / Delivery of Health Care / Precision Medicine / Pharmacogenomic Testing Type of study: Prognostic_studies / Qualitative_research Limits: Adolescent / Adult / Female / Humans / Male / Middle aged Language: En Journal: Pharmacogenomics Journal subject: FARMACOLOGIA / GENETICA MEDICA Year: 2018 Type: Article Affiliation country: United States

Full text: 1 Database: MEDLINE Main subject: Pharmacogenetics / Delivery of Health Care / Precision Medicine / Pharmacogenomic Testing Type of study: Prognostic_studies / Qualitative_research Limits: Adolescent / Adult / Female / Humans / Male / Middle aged Language: En Journal: Pharmacogenomics Journal subject: FARMACOLOGIA / GENETICA MEDICA Year: 2018 Type: Article Affiliation country: United States